Celebrating 20 years of the Stanley J. Korsmeyer Award

This year, the ASCI is celebrating the 20th anniversary of the Stanley J. Korsmeyer Award, which has become a beacon of excellence by celebrating key discoveries made by physician-scientists who are also passionate about mentoring.

At the upcoming Joint Meeting, on Friday, April 20, 5 to 5:30 p.m., the ASCI will recognize Dr. Joseph Heitman as the 2018 Korsmeyer Award recipient. His presentation for the Korsmeyer Lecture is “Natural product drug targets are conserved from model and pathogenic yeasts to humans.”

Also on Friday, April 20, Benjamin L. Ebert, MD, PhD, the 2017-2018 ASCI President, will host his President’s Reception from 6 to 7:15 p.m. in honor of this milestone for the Korsmeyer Award. The reception will feature introductory remarks from Dr. Ebert followed by reminiscences from:

  • Susan Korsmeyer, Dr. Korsmeyer’s widow and a staunch advocate for the Award and its legacy
  • Scott A. Armstrong, MD, PhD, a former trainee of Dr. Korsmeyer and currently Chair of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute
  • Timothy J. Ley, MD, a former colleague of Dr. Korsmeyer and currently Associate Director for Cancer Genomics, The Genome Institute, Washington University, St. Louis

In connection with celebrating the significant history of the Award and recognizing Dr. Korsmeyer, the ASCI is seeking the support of the physician-scientist community to sustain the Award’s legacy. Your gift to the Korsmeyer Award Fund, which will be restricted to the Award, will highlight your commitment to this critical recognition and the impact it has had, and will continue to have, on the physician-scientist community.

It is an honor for me to join Susan Korsmeyer and Carnell Korsmeyer (Dr. Korsmeyer’s mother) in a combined Visionary donation toward the fund. I am pleased to recognize other initial donors: Louis J. Ptáček, MD (2015 Award recipient), James E. Crowe Jr., MD (2017 Award recipient), and Kieren Marr, MD (Chair, ASCI Development Committee).

I hope that you will be able to join us in celebrating the Stanley J. Korsmeyer Award and its legacy:

https://www.the-asci.org/awards/korsmeyer/k20

As ever, thank you for your time.

John B. Hawley
Executive Director
The American Society for Clinical Investigation

2018 omnibus appropriations: great news for research funding

Dear ASCI member,

A part of our mission as a community of physician-scientists is to advocate for medical research and for measures that sustain the pipeline of young physicians to engage in research careers. In 2017, we formed an Advocacy Committee to work more closely with FASEB and Research!America, our advocacy partner organizations. Member Alp Ikizler serves as a member of FASEB’s Board of Directors, Council member Donna Martin serves on FASEB’s Science Policy Committee, and I serve as a liaison to the FASEB Board of Directors.

Earlier this spring, Donna Martin was the ASCI representative attending FASEB’s Capitol Hill Day, meeting with representatives to convey the value of investment in the U.S. research infrastructure.

FASEB staff have agreed to work with us to generate timely updates about the activities on Capitol Hill of value to ASCI members. Following is brief detail regarding the passage of the FY 2018 omnibus appropriations bill:

At 12:21 am Friday the Senate passed the fiscal year (FY) 2018 omnibus appropriations bill by a vote of 65-32. President Trump signed the bill into law Friday afternoon. Although it could take another 30 days for the new funds to be made available to the federal agencies, we can officially celebrate the $3 billion increase for NIH, $295 million increase for NSF, $868 million increase for DOE SC, $47 million increase for veterans research, and $25 million increase for competitive agriculture research.

Please see FASEB’s summary (PDF) for more information.

Look out for more information to come.

W. Kimryn Rathmell, MD, PhD
Chair, Advocacy Committee
The American Society for Clinical Investigation
www.the-asci.org
Follow us on Twitter: www.twitter.com/the_asci

The 2018 Harrington Prize for Innovation in Medicine: Helen H. Hobbs, MD

2018 Harrington Prize awarded to Dr. Helen Hobbs, University of Texas Southwestern Medical Center, for her advancements in biomedical science

The fifth annual Harrington Prize for Innovation in Medicine has been awarded to Helen H. Hobbs, MD, investigator of the Howard Hughes Medical Institute and Professor of Internal Medicine and Molecular Genetics at the University of Texas Southwestern Medical Center.

The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio, and The American Society for Clinical Investigation (ASCI), honors physician-scientists who have moved science forward with achievements notable for innovation, creativity, and potential for clinical application.

Dr. Hobbs is being recognized for her outstanding contributions to medicine and science. Her discovery of the link between a gene mutation (PCSK9) and lower levels of LDL, or “bad cholesterol,” is considered a major breakthrough and has improved the treatment of high cholesterol. Dr. Hobbs made the discovery when she sequenced the PCSK9 gene in subjects from a population-based study of 3,500 residents of Dallas County, Texas. She found that subjects with this particular mutation not only had lower LDL levels, but also had an 88% lower incidence of heart attacks as compared with the controls in the study. The discovery of this critical link has enabled the development of therapeutics that can effectively target the gene in order to lower LDL and the risk of heart attack.

“Dr. Hobbs’ research has had a profound impact on human health,” said Benjamin Ebert, MD, PhD, Chair of Medical Oncology at the Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and 2017-2018 President of the ASCI. “Her ground-breaking discovery of PCSK9’s connection to cholesterol has led to the development of an FDA-approved therapy within 10 years, which is a remarkable achievement.”

A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from three countries before selecting the 2018 recipient.

“We are pleased to join with the ASCI to honor Dr. Hobbs for her pioneering studies in human genetics that have advanced the standard of care,” said Jonathan Stamler, MD, President of the Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at UH Cleveland Medical Center and Case Western Reserve University School of Medicine. “Her superb work clearly exemplifies the guiding principles of The Harrington Prize, which recognizes the most innovative and creative investigators to have impacted patients’ lives.”

In addition to receiving a $20,000 honorarium, Dr. Hobbs will deliver the Harrington Prize Lecture at the 2018 AAP/ASCI/APSA Joint Meeting on April 20, 2018, and publish an essay in the Journal of Clinical Investigation.

Dr. Hobbs, Director of the Eugene McDermott Center for Human Growth and Development, received her MD from Case Western Reserve University in 1979. She is currently Director of the Dallas Heart Study, a longitudinal, multiethnic, population-based study of Dallas County in Texas. Dr. Hobbs holds the Eugene McDermott Distinguished Chair for the Study of Human Growth and Development, Philip O’Bryan Montgomery, Jr., M.D. Distinguished Chair in Developmental Biology, and the 1995 Dallas Heart Ball Chair in Cardiology Research.

The first recipient of The Harrington Prize for Innovation in Medicine, in 2014, was Dr. Harry Dietz (Johns Hopkins University School of Medicine, USA), a pediatric cardiologist and genetics researcher, for his contributions to the understanding of the biology and treatment of Marfan syndrome, a disorder leading to deadly aneurysms in children and adults. The 2015 recipient was Douglas R. Lowy, MD, Chief, Laboratory of Cellular Oncology (The National Cancer Institute, USA), in recognition of his discoveries that led to the development of the Human Papillomavirus (HPV) vaccine to prevent cervical cancer. The 2016 recipient was Jeffrey M. Friedman, MD, PhD (The Rockefeller University, USA), for his discovery of leptin, which controls feeding behavior and is used to treat related clinical disorders. In 2017, the Prize was awarded jointly to Daniel J. Drucker, MD (Mount Sinai Hospital, Canada), Joel F. Habener, MD (Massachusetts General Hospital, USA) and Jens J. Holst, MD, DMSc (University of Copenhagen, Denmark) for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes.

Harrington Discovery Institute

The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.

The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.

For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.

University Hospitals

Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 40 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio. The system’s flagship academic medical center, University Hospitals Cleveland Medical Center, located on a 35-acre campus in Cleveland’s University Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children’s Hospital, ranked among the top children’s hospitals in the nation; University Hospitals MacDonald Women’s Hospital, Ohio’s only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer, pediatrics, women’s health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. UH is one of the largest employers in Northeast Ohio with 26,000 employees.

UH’s vision is “Advancing the science of health and the art of compassion,” and its mission: “To Heal. To Teach. To Discover.” Follow UH on Facebook @UniversityHospitals and Twitter @UHhospitals. For more information, go to UHhospitals.org.